Table 1.
Genes with differential expression correlated to treatment response.
| Gene | Mean | Log2FC (SE) | FDR | PVE (%) | p value MADRS BL | p value treatment |
|---|---|---|---|---|---|---|
| Baseline and week 8 | ||||||
| PROK2 | 146.54 | −0.014 (0.0025) | 0.0028 | 2.38 | 0.88 | 1.00 |
| SOCS3 | 76.70 | −0.016 (0.0031) | 0.0039 | 5.52 | 0.93 | 0.11 |
| GCA | 663.43 | −0.006 (0.0012) | 0.0075 | 0.58 | 0.65 | 0.43 |
| GALNT14 | 7.61 | −0.017 (0.0035) | 0.015 | 3.07 | 0.67 | 0.72 |
| UBE2J1 | 210.26 | −0.008 (0.0017) | 0.017 | 2.13 | 0.59 | 0.025 |
| GNG10 | 48.91 | −0.011 (0.0025) | 0.017 | 0.49 | 0.15 | 0.96 |
| FRAT2 | 286.38 | −0.0057 (0.0013) | 0.022 | 1.31 | 0.85 | 0.62 |
| ADK | 39.45 | −0.0084 (0.0019) | 0.024 | 2.81 | 0.049 | 0.85 |
| PSG4 | 2.55 | −0.027 (0.0063) | 0.042 | 3.19 | 0.93 | 0.72 |
Mean = mean of counts per million using DREAM; Log2FC (SE) = log2 fold change (standard error); FDR = BH adjusted p value; PVE = Proportion of Variance in gene expression Explained by treatment response; p value MADRS BL = p value of association between gene expression and depression symptom severity at baseline; p value treatment = p value of the interaction effect between treatment response and treatment type. Significant genes are in italics.